BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/3/2020 1:28:57 AM | Browse: 701 | Download: 1076
 |
Received |
|
2019-07-01 01:01 |
|
Peer-Review Started |
|
2019-07-01 05:42 |
|
To Make the First Decision |
|
2019-08-14 06:51 |
|
Return for Revision |
|
2019-08-14 07:01 |
|
Revised |
|
2019-09-30 19:26 |
|
Second Decision |
|
2019-12-05 09:17 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-12-09 04:48 |
|
Articles in Press |
|
2019-12-09 04:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-12-20 08:11 |
|
Publish the Manuscript Online |
|
2020-01-03 01:28 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fiona Chautant, Maeva Guillaume, Marie-Angèle Robic, Jean-François Cadranel, Jean-Marie Péron, Hortensia Lison, Charlène Cool, Christophe Bureau and Véronique Duhalde |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fiona Chautant, PharmD, Pharmacist, Department of Pharmacy, University Hospital Toulouse, 330 avenue de Grande Bretagne, Toulouse 31059, France. fiona.chautant@gmail.com |
| Key Words |
Rifaximin; Hepatic encephalopathy; Cirrhosis; Liver disease; Hospitalization; |
| Core Tip |
The clinical and economic burdens of hepatic encephalopathy (HE) are tremendous and growing worldwide. Therapies to improve the quality of life of patients and to decrease the rate of hospitalizations and economic consequences are needed. Rifaximin was proved effective to reduce the risk of HE recurrence in patients with episodic forms. However, real-life data are still scarce, particularly concerning persistent HE. In this real-life experience, the effectiveness of rifaximin was confirmed in the prevention of HE episodes recurrence but was not proved in the management of persistent HE. |
| Publish Date |
2020-01-03 01:28 |
| Citation |
Chautant F, Guillaume M, Robic MA, Cadranel JF, Peron JM, Lison H, Cool C, Bureau C, Duhalde V. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy. World J Hepatol 2020; 12(1): 10-20 |
| URL |
https://www.wjgnet.com/1948-5182/full/v12/i1/10.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v12.i1.10 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
